GSK’s latest phase III shingles trial offers hope to stem cell transplant patients
People who have undergone stem cell transplants typically have weaker immune systems, which makes them more susceptible to viruses such as shingles
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 27 of 38
GSK’s ViiV Healthcare kicks off enrolment of big phase III HIV trial in Africa
The trial will evaluate the effectiveness of an injectable HIV drug, administered only once every two months, in sexually active women
Investments and investor services
Parallel Media and Physiomics lead small cap market gainers
Some of the biggest risers and fallers in London on Wednesday
Investments and investor services
FTSE 100 closes lower as pound firms amid Brexit bill breakthrough
London's blue-chip index closed the day lower but retailers and housebuilders did well, oh, and there was some Brexit news...
UBS reckons GSK is a ‘buy’, citing weak share price and secure dividend
Uncertainty surrounding the trajectory of GSK’s ViiV Healthcare HIV business justifies a discount argues UBS analyst Michael Leutchen, but he reckons the valuation now reflects that
GSK steals a march on rivals as its two drug, one pill HIV treatment gets green light from FDA
Juluca – as the treatment is known – is made by GSK’s majority-controlled ViiV Healthcare and is the first such drug to be approved by US authorities
New HIV and lung drugs help boost GSK’s Q3 sales but investors hoped for more
The strong demand for Tivicay and Relvar, among others, justifies new boss Emma Walmsley’s decision to narrow the drugmaker’s focus on HIV and respiratory medicines
Investments and investor services
FTSE 100 closes over 1% lower as sterling spikes
The UK blue chip index closed down 1.05% to 7,447 as the pound strengthened after better-than-forecast UK GDP
Archive
Lloyds Banking looking to put its trials behind it
PPI, the HBOS acquisition and now the prospect of a rate rise hitting the mortgage market; it's all a bit of a trial for Lloyds
GSK gets approvals for 'bubble boy' syndrome gene therapy in UK and shingles vaccine in US
The UK healthcare cost regulator has approved GSK's gene therapy for so-called 'bubble boy' syndrome while the US FDA has approved its shingles vaccine
Lloyds, Barclays and RBS under the microscope with release of third quarter earnings
The week ahead includes third quarter earnings from Lloyds, Barclays and RBS along with trading updates from Shire, IAG and GSK
Koovs jumps on partnership deal with online clothing retailer N Brown
A look at some of the biggest risers and fallers today in London
FTSE 100 closes in negative territory despite resource stock gains
The UK blue chip index closed at 7,526, well below the session peak of 7,557.00 and close to the day’s low of 7,531.48
GlaxoSmithKline gets 'positive opinion' from EMA panel for three-in-one inhaled COPD treatment
The once-a-day triple inhaler combines the drugs fluticasone furoate, umeclidinium and vilanterol and will have a proposed brand name of Trelegy Ellipta
Shire, AstraZeneca and GSK in the red as JP Morgan looks at risks facing pharmaceutical sector
Shire remains the "standout stock" as it has an "extremely compelling valuation”, according to JP Morgan
GSK asthma study results published in medical journal and presented at industry meeting
A study of GSK's Relvar Eillipta treatment showed an improvement in symptoms of asthma sufferers
FTSE 100 trims losses
The FTSE 100 retreated as investors worry about Hurricane Irma, while mixed economic statistics raised fresh concerns over the UK economy.
Analyst thinks Vectura share price drop may not just be due to bigger pre-tax loss
Mike van Dulken, head of research at Accendo Markets said the share price reaction “may in fact be due to a downgraded Risk & Uncertainties statement, buried half way through the report before the financial statements"
FTSE 100 plunges on North Korea fears
The FTSE 100 finished 108 points lower at 7,390, about 13 points above its intra-day low
United Therapeutics opens 10% higher as GlaxoSmithKline is named as a potential bidder for the group
Sources are cited as saying the bidding could go as high as US$200 a share, valuing the business at US$8.7bn